APUS

Apimeds Pharmaceuticals US, Inc.

NYSE MKT: APUS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$3.07

+0.66% today

Updated 2026-10-28

Market cap

$6.10M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-36.03

Dividend yield

—

52W range

$2 – $40

Volume

4.7M

Market cap

$6.10M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-36.03

Dividend yield

—

52W range

$2 – $40

Volume

4.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

8.3

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →270 stocks currently score above 75

Price targets

Analyst target

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

+ Altman Z 8.31 — safe zone

+ Debt/equity 0.14x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-6.18M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-668666.00	$-777694.00	$-1.39M	$-6.00M	$-20.17M
EPS	—	—	—	—	$-36.03
Free cash flow	$-448167.00	$-627790.00	$-733526.00	$-8.98M	$-6.18M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
APUS	$6.10M	27	4.3	3.0	5.0	6.5	—	Avoid
LLY	$1.12T	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$615.87B	57	4.7	8.5	2.7	5.5	-83.05%	Buy
ABBV	$504.37B	73	6.7	8.5	4.0	5.0	-86.73%	Strong Buy
UNH	$360.32B	62	6.7	6.0	4.7	5.5	-25.92%	Buy
MRK	$360.08B	36	4.0	4.5	2.0	5.0	-73.68%	Hold

Smart narrative

Apimeds Pharmaceuticals US, Inc. trades at $3.07. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 8.31, it sits in the safe zone.

Frequently asked questions

What is Apimeds Pharmaceuticals US, Inc.'s stock price?

Apimeds Pharmaceuticals US, Inc. (APUS) trades at $3.07.

Is Apimeds Pharmaceuticals US, Inc. overvalued?

Apimeds Pharmaceuticals US, Inc. carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

Altman Z-Score?

Apimeds Pharmaceuticals US, Inc.'s Altman Z-Score is 8.31, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

www.mindwavedao.com

Quick metrics

P/S ratio—

ROE-63.20%

Beta—

50D MA$3.95

200D MA$11.60

Shares out0.00B

Float0.00B

Short ratio—

Avg volume4.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

APUS vs LLY →APUS vs JNJ →APUS vs ABBV →Stock screener →